» Articles » PMID: 2385079

Glomerular Hypertrophy in Minimal Change Disease Predicts Subsequent Progression to Focal Glomerular Sclerosis

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 1990 Jul 1
PMID 2385079
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

The study sought a diagnostic clue to identify the group of pediatric patients with apparent minimal change disease who subsequently develop focal glomerular sclerosis (FGS). Review of all renal biopsy material at our institutions identified 42 pediatric patients who met the standard criteria for minimal change disease (MCD) on initial biopsies. Of those, 10 deteriorated clinically and on rebiopsy showed focal glomerular sclerosis (FGS). The initial renal biopsies of these 10 patients were analyzed morphometrically to determine the mean glomerular tuft area (GA). The results were compared to those of the remaining 32 patients whose subsequent benign clinical course was consistent with MCD, and to randomly selected, age-matched autopsy controls without renal disease (CONT, N = 10). The mean age was comparable among the three groups studied. Separate groups of adult (N = 12) and pediatric (N = 18) patients with initial biopsies with FGS were also studied. The initial biopsy of pediatric patients who subsequently showed FGS (rebiopsy performed on average 3.3 years later) had an average GA of 13.5 x 10(-3) mm2, 76% larger than glomeruli from children with MCD (7.7 x 10(-3) mm2, P less than 0.0005) and 62% larger than CONT (8.4 x 10(-3) mm2, P less than 0.005). Patients with FGS on initial biopsy, whether adult or pediatric, also had significantly larger GA than the age-matched MCD or CONT groups. Evaluation of GA in all the 42 pediatric biopsies with initial MCD further showed that in 23 patients GA was equal to or smaller than the CONT average.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Glomerular Diameter Measurements on Light Microscopy: A New Parameter Available to Pathologists and its Utility in IgA Nephropathy.

Manocha A, Fathima N, Gowrishankar S Indian J Nephrol. 2024; 34(4):344-349.

PMID: 39156857 PMC: 11326795. DOI: 10.25259/ijn_361_23.


Decoding pathology: the role of computational pathology in research and diagnostics.

Holscher D, Bulow R Pflugers Arch. 2024; .

PMID: 39095655 DOI: 10.1007/s00424-024-03002-2.


Glomerular hyperfiltration and hypertrophy: an evaluation of maximum values in pathological indicators to discriminate "diseased" from "normal".

Kataoka H, Nitta K, Hoshino J Front Med (Lausanne). 2023; 10:1179834.

PMID: 37521339 PMC: 10372422. DOI: 10.3389/fmed.2023.1179834.


Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.

Zhang J, Zhao H, Li X, Qian R, Gao P, Lu S BMC Nephrol. 2023; 24(1):112.

PMID: 37101300 PMC: 10134665. DOI: 10.1186/s12882-023-03092-7.


Next-Generation Morphometry for pathomics-data mining in histopathology.

Holscher D, Bouteldja N, Joodaki M, Russo M, Lan Y, Vafaei Sadr A Nat Commun. 2023; 14(1):470.

PMID: 36709324 PMC: 9884209. DOI: 10.1038/s41467-023-36173-0.